 MAP Kinase Kinase Kinase 3
"MAP Kinase Kinase Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 70-kDa MAPK kinase kinase with specificity for MAP KINASE KINASE 5.
| Descriptor ID |
D048748
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.559.300 D12.644.360.400.300 D12.776.476.400.300
|
| Concept/Terms |
MAP Kinase Kinase Kinase 3- MAP Kinase Kinase Kinase 3
- MAPK-ERK Kinase Kinase 3
- MAPK ERK Kinase Kinase 3
- MEK Kinase 3
- ERK Kinase Kinase 3
- Mitogen-Activated Protein Kinase Kinase Kinase 3
- Mitogen Activated Protein Kinase Kinase Kinase 3
- MAP3K3 Protein Kinase
- Protein Kinase, MAP3K3
- MEKK3 Protein Kinase
- Protein Kinase, MEKK3
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase Kinase 3".
This graph shows the total number of publications written about "MAP Kinase Kinase Kinase 3" by people in this website by year, and whether "MAP Kinase Kinase Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 | | 2020 | 0 | 2 | 2 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "MAP Kinase Kinase Kinase 3" by people in Profiles.
-
Ren AA, Snellings DA, Su YS, Hong CC, Castro M, Tang AT, Detter MR, Hobson N, Girard R, Romanos S, Lightle R, Moore T, Shenkar R, Benavides C, Beaman MM, Müller-Fielitz H, Chen M, Mericko P, Yang J, Sung DC, Lawton MT, Ruppert JM, Schwaninger M, Körbelin J, Potente M, Awad IA, Marchuk DA, Kahn ML. PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature. 2021 06; 594(7862):271-276.
-
Wei S, Li Y, Polster SP, Weber CR, Awad IA, Shen L. Cerebral Cavernous Malformation Proteins in Barrier Maintenance and Regulation. Int J Mol Sci. 2020 Jan 20; 21(2).
-
Koskimäki J, Zhang D, Carrión-Penagos J, Girard R, Piedad K, Polster SP, Lyne S, Stadnik A, Awad IA. Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature. World Neurosurg. 2020 Apr; 136:7-11.
-
Zhou Z, Tang AT, Wong WY, Bamezai S, Goddard LM, Shenkar R, Zhou S, Yang J, Wright AC, Foley M, Arthur JS, Whitehead KJ, Awad IA, Li DY, Zheng X, Kahn ML. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature. 2016 Apr 07; 532(7597):122-6.
-
Luke JJ, Ott PA, Shapiro GI. The biology and clinical development of MEK inhibitors for cancer. Drugs. 2014 Dec; 74(18):2111-28.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|